Leadership

Led by an entrepreneurial and experienced management team, supported by a distinguished Board

Executive team

Dr James McIlroy

MBChB, BMedSci (Hons)
CEO & BOARD MEMBER
Qualified medical doctor. Formed company, raised >£50m, initiated and completed Ph2 clinical trials with positive data
Dr James Barnes

PhD
COO
~20 years of strategic leadership, drug development & business operations. Previously worked as COO at BerGenBio ASA and at Vertex Pharmaceuticals
Melissa Strange

FCCA, MBA, LLB (Hons)
CHIEF FINANCIAL OFFICER
>15 years strategic financial leadership experience in drug development. Actively involved in raising $100m for private and public companies
Elmar Schnee

MA
EXECUTIVE CHAIRMAN
Previously CEO of Merck Serono. Highly experienced Board Chairman in drug development companies
Kimberley McAleney

PGD
DIRECTOR OF PEOPLE & CULTURE
Extensive experience in the design and successful execution of HR strategy, supporting fast-paced scaling businesses across a variety of industries, including life sciences
Dr Thomas Knittel

MD, MBA
SENIOR MEDICAL ADVISOR
Gastroenterologist with >20+ years of industry experience in large pharma and small biotech. Designed and completed Ph3 GI trials
Andrew Thompson

HEAD OF BUSINESS DEVELOPMENT
Seasoned Business Development executive with deep expertise and strong track record in GI and liver

Board of Directors

Felix Olale

Non-Executive Director
CEO at Medgenome North America and Europe. Sits as Chairman of MedGenome and Director of Ascent Meditech
Iain Baird

Investor Director
Principal, Development Solutions. >35 years of operational and leadership experience in the pharma industry
Mark Bamforth

Investor Director
Founder and CEO of ArrantaBio (acquired by Recipharm), Brammer Bio (acquired by Thermofisher)
Douglas Thomson

Investor Director
CEO and co-founder at Pneumagen Limited, a clinical phase anti-infective company
David Lawrence

Independent NXD
Previously CFO Valneva. Delivered 2021 NASDAQ IPO